~~<i id='807EB1D7C8'><strike id='807EB1D7C8'><tt id='807EB1D7C8'><pre id='807EB1D7C8'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：knowledge 2025-10-01 14:41:15 Page View：6

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How a scoliosis diagnosis changed the life of one young dancer
Next article： Walensky prepares to leave CDC — and Congress — behind

knowledge

Hollywood unions extend contract negotiations for actors

1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

3 medical device trends to watch in 2024

ChristineKao/STATIt’sbeenaslowyearformedtech.Majordealsin2023werescarce,fundingwashardtocomeby,andva

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

How a key Senate committee is planning to regulate PBMs

DraftlegislationauthoredbySenateFinanceChairRonWyden(D-Ore.)andrankingmemberMikeCrapo(R-Idaho)includ

WSS

explore

explore

focus

knowledge

How a key Senate committee is planning to regulate PBMs